title: Hepatitis G virus infection in a haemodialysis unit: prevalence and clinical implications.
abstract: BACKGROUND
  Hepatitis viruses have become one of the main infectious problems in patients on long-term haemodialysis. A new RNA virus, designated hepatitis G virus (HGV) has been recently identified. The pathogenic relevance of this virus is currently under investigation. The aim of this study was to analyse the prevalence and clinical implications of hepatitis G virus infection in patients on haemodialysis.
  
  
  METHODS
  The presence of HGV-RNA was investigated in 96 patients on maintenance haemodialysis. Hepatitis viral markers (HBsAg, anti-HCV, HGV-RNA) and liver tests were assessed in all these patients, as well as the risk factors for hepatitis viruses acquisition. As a control group, 200 blood donors were tested for the presence of HGV-RNA.
  
  
  RESULTS
  HGV-RNA was detected in 25 of 96 patients on haemodialysis (26%) and in six of 200 blood donors (3%) (P < 0.001). Thirteen of 25 HGV infected patients (52%) were coinfected with other hepatitis viruses (HBV and/or HCV). Evidences of chronic liver disease were more frequent in patients infected by HBV and/or HCV (61%) than in patients infected by HGV alone (17%) (P = 0.01). Although 80% of HGV infected patients had received blood products, the transfusion rate was not different from non HGV-infected patients. Time on haemodialysis was significantly shorter in patients infected with HGV alone (3.1 +/- 3.5 years) compared to patients infected with HBV and/or HCV (7.6 +/- 5.8 years) (P = 0.04).
  
  
  CONCLUSIONS
  Patients on maintenance haemodialysis are at increased risk for HGV infection. HGV infection itself does not seem to be a frequent cause of chronic liver disease in these patients. Since the prevalence of HGV infection in blood donors is high, blood transfusion could be one of the main factors implicated in HGV transmission in patients on haemodialysis.
authors.affiliation: Liver Unit, Hospital Clínic i Provincial, Barcelona, Spain.
authors.forename: X
authors.initials: X
authors.lastname: Forns
authors.forename: P
authors.initials: P
authors.lastname: Fernández-Llama
authors.forename: J
authors.initials: J
authors.lastname: Costa
authors.forename: F X
authors.initials: FX
authors.lastname: López-Labrador
authors.forename: S
authors.initials: S
authors.lastname: Ampurdanés
authors.forename: E
authors.initials: E
authors.lastname: Olmedo
authors.forename: J C
authors.initials: JC
authors.lastname: Saiz
authors.forename: M
authors.initials: M
authors.lastname: Guilera
authors.forename: J
authors.initials: J
authors.lastname: López-Pedret
authors.forename: J M
authors.initials: JM
authors.lastname: Sánchez-Tapias
authors.forename: A
authors.initials: A
authors.lastname: Darnell
authors.forename: M T
authors.initials: MT
authors.lastname: Jimenez de Anta
authors.forename: A
authors.initials: A
authors.lastname: Ordinas
authors.forename: J
authors.initials: J
authors.lastname: Rodés
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D018067:Flaviviridae / Q000302:isolation & purification; D006436:Hemodialysis Units, Hospital; D006525:Hepatitis, Viral, Human / Q000453:epidemiology* / Q000635:transmission*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects*; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D065227:Transfusion Reaction
chemical_list: D012367:RNA, Viral